From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

  1. Home>
  2. Specialties>
  3. General Medicine>
  4. Summary and Comment

Does BNP Testing Reduce Hospital Utilization?

Incorporating BNP results with other clinical information improved the evaluation of dyspnea patients in the ED.

B-type natriuretic peptide (BNP) levels now are measured routinely in many emergency departments (EDs). Although high levels of BNP are associated with heart failure in dyspneic patients, the effect of BNP levels on clinical outcomes is uncertain.

In this Swiss randomized trial, 452 patients who presented to an ED with acute dyspnea were evaluated and managed either with or without BNP testing. Heart failure was considered unlikely when BNP levels were lower than 100 pg/mL and likely when BNP levels exceeded 500 pg/mL. Compared with the control group, the BNP group had significantly lower rates of hospitalization (85% vs. 75%) and intensive-care-unit admission (24% vs. 15%), shorter hospital stays (median, 11 vs. 8 days), and lower treatment costs (US$7264 vs. $5410). In-hospital mortality, 30-day mortality, and 30-day rehospitalization rates were similar in the 2 groups. BNP patients were more likely than controls to receive final diagnoses of chronic obstructive pulmonary disease exacerbation (23% vs. 11%).

Comment: In this study of acutely dyspneic patients, measuring BNP was associated with substantial reductions in hospitalization rates and costs. The authors don't provide much detail to explain how these benefits were achieved, but one clue is the greater propensity to diagnose COPD when BNP was measured; if some of these patients would have been misdiagnosed without BNP testing, they might have received inappropriate initial treatment. These findings should be validated in other studies that tell us how often BNP testing simply reinforces our clinical judgments and how often it actually overturns incorrect diagnoses.

— Allan S. Brett, MD

Published in Journal Watch General Medicine February 20, 2004

Citation(s):

Mueller C et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004 Feb 12; 350:647-54.

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

The editors of Journal Watch may respond to Reader Remarks, but we cannot promise to respond to a particular remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Sign-In

Forgot your password? Login via Athens
or your institution

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2004. Massachusetts Medical Society. All rights reserved.